HCV Program Progress and Clinical Data The BEM/RZR combination demonstrated impressive efficacy in Phase 2 trials, achieving a 98% sustained virologic response at 12 weeks post-treatment (SVR12) in ...

Since its launch in 2016, a hepatitis C elimination program in Iceland has treated approximately 56% to 70% of the estimated viremic population with direct-acting antivirals, according to a recently ...

Please provide your email address to receive an email when new articles are posted on . In collaboration with the CDC, the country of Georgia launched a hepatitis C virus infection elimination program ...

C-FORWARD is the Second Phase 3 Trial in the Global HCV Development Program; the First Phase 3 Trial, C-BEYOND, is Currently Enrolling Patients in the US and Canada Regimen has Potential Best-in-Class ...

Good day, ladies and gentlemen, and welcome to the Abbott HCV Program Update. My name is Caris, and I will be your coordinator for today. [Operator Instructions] As a reminder, this call is being ...

Enrollment Completed in C-BEYOND Phase 3 Trial with More Than 880 HCV Treatment-Naïve Patients in US and CanadaC-BEYOND Topline Results Expected ...

Atea Pharmaceuticals (AVIR) offers a late-stage, best-in-class HCV cure, with significant upside, currently trading below cash. BEM/RZR combines advantages of current first-line HCV therapies — single ...

The study, which was an open multi-cohort Markov model, aimed to analyze the clinical and economic outcomes of the United States HCV population from 2018 on. For patients with non-cirrhotic chronic ...

AbbVie ( ABBV) presented positive data from a phase III study, TURQUOISE-II, on its investigational hepatitis C virus (HCV) regimen at the recently held International Liver Congress. The results from ...

Regulus Therapeutics Inc. is halting development of its lead microRNA candidate, RG-101, an N-acetylgalactosamine (GalNAc)-conjugated asset targeting miR-122 in chronic hepatitis C virus (HCV), rather ...